secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001628280-25-018908
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics posts Q2 2025 corporate presentation; no new material data disclosed
--------------------------------------------------------------------------------

- Presentation references lead candidate INT230-6 and DfuseRx platform for solid tumor treatment.
- No specific clinical results, financial updates, or guidance changes are included in the filed excerpt.
- Document furnished under Regulation FD; not deemed filed for SEC liability purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000162828025018908/0001628280-25-018908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000162828025018908/intensity-20250422.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-018908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer